Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Relacorilant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Corcept Shows Relacorilant Improves Survival In Ovarian Cancer
    Corcept Shows Relacorilant Improves Survival In Ovarian Cancer

    02 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250602291571/en/Corcept-Presents-Pivotal-Clinical-Data-in-ASCO-Late-Breaker-with-Simultaneous-Publication-in-The-Lancet-Relacorilant-Improves-Progression-Free-and-Overall-Survival-in-Patients-with-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    02 Jun 2025
    Share Share
    Corcept to present late-breaking data from Rosella trial at ASCO Meeting
    Corcept to present late-breaking data from Rosella trial at ASCO Meeting

    23 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250422468615/en/CORCEPT-TO-PRESENT-LATE-BREAKING-DATA-FROM-PIVOTAL-PHASE-3-ROSELLA-TRIAL-OF-RELACORILANT-IN-PLATINUM-RESISTANT-OVARIAN-CANCER-AT-ASCO-2025

    BUSINESSWIRE
    23 Apr 2025
    Share Share
    Corcept Starts Trial in Platinum-Resistant Ovarian Cancer
    Corcept Starts Trial in Platinum-Resistant Ovarian Cancer

    07 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250407805321/en/Corcept-Initiates-Trial-of-Relacorilant-Plus-Nab-Paclitaxel-and-Bevacizumab-in-Patients-With-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    07 Apr 2025
    Share Share
    FDA Files Corcept's NDA for Relacorilant in Hypercortisolism
    FDA Files Corcept's NDA for Relacorilant in Hypercortisolism

    03 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250303227690/en

    BUSINESSWIRE
    03 Mar 2025
    Share Share
    Corcept Submits NDA for Relacorilant in Hypercortisolism
    Corcept Submits NDA for Relacorilant in Hypercortisolism

    30 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241230947567/en

    BUSINESSWIRE
    30 Dec 2024
    Share Share
    Corcept’s Relacorilant Ph 3 Shows Cardiometabolic Improvements
    Corcept’s Relacorilant Ph 3 Shows Cardiometabolic Improvements

    16 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241216461773/en

    BUSINESSWIRE
    16 Dec 2024
    Share Share